Concetta C.
- Country
- Italy
- Department
- U.O di Ematologia con Trapianto di Midollo Osseo
Research Overview
- AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPd), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3)
- Phase 3 Randomized Study of Iberdomide, Daratumumab, and Dexamethasone vs. Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
- Phase 3 Study of Daratumumab, Lenalidomide, Dexamethasone, and Linvoseltamab in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients
Data & Insights
Has run more than one trial at 39 of 144 partner sites.
Specializations
Hematologic Oncology
This investigator specializes in treating multiple myeloma, with particular emphasis on managing relapsed and refractory cases. Their research focuses on innovative therapeutic combinations for blood cancer treatment.
- Multiple Myeloma Management
- Blood Cancer Therapeutics
- Treatment-Resistant Disease
The investigator evaluates novel therapeutic approaches for patients whose condition has progressed despite previous treatments.
Novel Drug Development
Expertise in studying emerging therapeutics including iberdomide and its combinations with established treatments like daratumumab. The research encompasses evaluation of innovative drug combinations for enhanced treatment outcomes.
- Combination Therapy Assessment
- Immunomodulatory Agents
- Treatment Optimization
Their work involves investigating therapeutic combinations that may improve responses in resistant disease cases.
Treatment Response Assessment
The investigator focuses on evaluating treatment efficacy through advanced metrics including minimal residual disease assessment and progression-free survival monitoring in blood cancer patients.
- Disease Response Monitoring
- Survival Outcomes Research
- Treatment Effectiveness Evaluation
Their research emphasizes precise measurement of therapeutic outcomes in hematologic malignancies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.